Home »
Academic Articles »
R »
Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents
Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents
Hoda Zarkoob
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Anna Allué-Guardia
(Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute)
Yu-Chi Chen
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Andreu Garcia-Vilanova
(Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute)
Olive Jung
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Steven Coon
(Molecular Genomics Core, National Institute of Child Health and Human Development, National Institutes of Health)
Min Jae Song
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Jun-Gyu Park
(Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute)
Fatai Oladunni
(Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute)
Jesse Miller
(Department of Biochemistry and Biophysics, University of Pennsylvania)
Yen-Ting Tung
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Ivan Kosik
(National Institute for Allergies and Infectious Diseases, National Institutes of Health)
David Schultz
(Department of Biochemistry and Biophysics, University of Pennsylvania)
James Iben
(Molecular Genomics Core, National Institute of Child Health and Human Development, National Institutes of Health)
Tianwei Li
(Molecular Genomics Core, National Institute of Child Health and Human Development, National Institutes of Health)
Jiaqi Fu
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Forbes D. Porter
(Section on Molecular Dysmorphology, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services)
Jonathan Yewdell
(National Institute for Allergies and Infectious Diseases, National Institutes of Health)
Luis Martinez-Sobrido
(Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute)
Sara Cherry
(Department of Biochemistry and Biophysics, University of Pennsylvania)
Jordi B. Torrelles
(Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute)
Marc Ferrer
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Emily M. Lee
(3D Tissue Bioprinting Lab, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health)
Human alveolar and tracheobronchial epithelial air liquid interface (ALI) tissues are used as models to examine cellular responses to SARS-CoV-2 and influenza A virus infections and as antiviral drug screening assay platforms.
Hoda Zarkoob, Anna Allué-Guardia, Yu-Chi Chen, et al. (2022). "Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents". Communications Biology. https://doi.org/10.1038/s42003-022-03753-7